See more : American Vanguard Corporation (AVD) Income Statement Analysis – Financial Results
Complete financial analysis of Greenwich LifeSciences, Inc. (GLSI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Greenwich LifeSciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- FLEX LNG Ltd. (FLNG) Income Statement Analysis – Financial Results
- Banyan Tree Holdings Limited (BYNEF) Income Statement Analysis – Financial Results
- GTL Infrastructure Limited (GTLINFRA.BO) Income Statement Analysis – Financial Results
- Harmoney Corp Limited (HMY.AX) Income Statement Analysis – Financial Results
- Sanyo Homes Corporation (1420.T) Income Statement Analysis – Financial Results
Greenwich LifeSciences, Inc. (GLSI)
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K |
| Gross Profit | -3.61K | -3.61K | -3.61K | -3.61K | -3.61K | -3.61K | -3.61K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.70M | 6.48M | 3.56M | 1.06M | 2.61M | 1.27M | 1.22M |
| General & Administrative | 1.63M | 1.56M | 1.04M | 806.19K | 818.89K | 419.64K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.63M | 1.56M | 1.04M | 806.19K | 818.89K | 419.64K | 346.81K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.33M | 8.04M | 4.60M | 1.86M | 3.43M | 1.69M | 1.57M |
| Cost & Expenses | 9.33M | 8.04M | 4.60M | 1.86M | 3.43M | 1.69M | 1.57M |
| Interest Income | 436.06K | 215.02K | 27.37K | 832.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K |
| EBITDA | -9.32M | -8.04M | -4.59M | -1.86M | -3.42M | -1.69M | -1.57M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.33M | -8.04M | -4.60M | -1.86M | -3.43M | -1.69M | -1.57M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 436.06K | 215.02K | 27.37K | 832.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -8.89M | -7.83M | -4.57M | -1.86M | -3.43M | -1.69M | -1.57M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -215.02K | -27.37K | -832.00 | 3.00 | -157.53K | 3.00 |
| Net Income | -8.89M | -7.61M | -4.54M | -1.86M | -3.43M | -1.69M | -1.57M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.69 | -0.59 | -0.35 | -0.15 | -0.29 | -0.14 | -0.13 |
| EPS Diluted | -0.69 | -0.59 | -0.35 | -0.15 | -0.29 | -0.14 | -0.13 |
| Weighted Avg Shares Out | 12.85M | 12.91M | 12.94M | 12.70M | 11.74M | 11.97M | 11.74M |
| Weighted Avg Shares Out (Dil) | 12.85M | 12.91M | 12.94M | 12.70M | 11.74M | 11.97M | 11.74M |
Greenwich LifeSciences Partners with GIM in Italy
STAFFORD, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced...
Greenwich LifeSciences Provides Update on Corporate Events
STAFFORD, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today...
Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain
STAFFORD, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced...
Greenwich LifeSciences: Halting Of Breast Cancer Recurrence With GLSI-100
Greenwich LifeSciences, Inc. approaches enrollment completion for the phase 3 Flamingo-01 study, using GLSI-100 for the treatment of patients with HER2/neu positive breast cancer, with full enrollment expected by the end of 2024. A prior phase 2b study indicated that...
Greenwich LifeSciences Set to Join Russell 2000 Index Again
STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced...
Greenwich LifeSciences Announces $2.5 Million Private Placement
STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company" or "Greenwich"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences,...
Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025
STAFFORD, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced...
Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe
STAFFORD, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced...
Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries
STAFFORD, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided...
Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators
STAFFORD, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients...
Source: https://incomestatements.info
Category: Stock Reports